Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Learn more about:
Related Clinical Trial
Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Official Title

A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma

Brief Summary

      The purpose of this study is to investigate other drugs that may be combined with radiation
      to treat cancer. The study focuses on determining whether a combination of durvalumab with
      radiation can both improve cure rate and at the same time have less serious side effects.
      Throughout this document, this investigational drug will be referred to as the "study drug",
      or named individually (durvalumab). The study drug in this research is referred to as
      investigational because the U.S. Food and Drug Administration (FDA) has not yet approved
      itfor the treatment of head and neck cancer. Durvalumab was FDA approved in 2017 for the
      treatment of certain types of bladder cancer, but has not been approved for use in Head and
      Neck cancer patients.

      Durvalumab is an experimental drug that uses the body's immune system to fight the cancer.
      This study drug is being used in other ongoing clinical trials for other types of cancers.
      The doctor feels that a patient may experience fewer side effects using this study drug with
      radiation rather than using cisplatin. The doctor is also investigating whether using this
      drug can increase the effectiveness of treatment.
    

Detailed Description

      Primary Objective -To estimate median 3-year disease free survival (DFS) in patients with
      intermediate-risk HNSCC treated with adjuvant durvalumab with radiotherapy.

      Secondary Objectives

        -  To characterize safety by evaluating Grade 3-4 acute toxicities of adjuvant durvalumab
           with radiotherapy in intermediate-risk HNSCC patients

        -  To characterize the Grade 3-4 chronic toxicities of adjuvant durvalumab with
           radiotherapy in intermediate-risk HNSCC patients.

        -  To characterize any-grade chronic toxicities of adjuvant durvalumab with radiotherapy in
           intermediate-risk HNSCC patients.

        -  To estimate median OS in patients with intermediate-risk HNSCC treated with adjuvant
           durvalumab with radiotherapy.

        -  To correlate PD-L1 expression with disease free survival

      Exploratory Objectives

        -  To analyze disease free survival by HPV status

        -  To determine how treatment with adjuvant durvalumab and radiotherapy changes markers of
           tumor infiltrating lymphocytes (TIL)

      Primary Endpoint

      -3-year DFS will be estimated via the Kaplan-Meier method. DFS is defined as the time from D1
      of treatment to time of disease recurrence or death

      Secondary Endpoints

        -  Grade 3-5 acute toxicity will be evaluated according to guidelines from NCI CTCAE, v5.0
           and include toxicity from the first day of treatment with immunotherapy until 30 days
           after completion of concurrent immunotherapy and radiation. Toxicity will include all
           toxicity attributed to the total study regimen (inclusive of radiation) not just to
           durvalumab alone.

        -  Grade chronic 3-5 toxicity will be evaluated according to guidelines from NCI CTCAE,
           v5.0 and include toxicity continuing or occurring 30 days after completion of concurrent
           immunotherapy and radiation, and will be followed for up to 6 months.

        -  OS will be estimated via the Kaplan-Meier method. OS is defined as the time from D1 of
           treatment to death from any cause.

        -  Measure PD-LI expression by immunohistochemistry. Pre-treatment PD-L1 expression will be
           correlated with disease free survival following treatment of adjuvant durvalumab with
           radiotherapy.

      Exploratory Endpoints

        -  Measure HPV status. HPV status will be correlated with disease free survival following
           treatment of adjuvant durvalumab with radiotherapy

        -  Measure tumor infiltrating lymphocytes (TIL) by flow cytometry at baseline
           (post-surgical, pre-treatment tissue) and at disease progression (post-treatment
           tissue). Changes in TIL levels will be compared between these two time points.

      Treatment Dosage This Phase II trial will evaluate the combination of durvalumab with
      radiation therapy as post-operative therapy in intermediate risk patients with HNSCC. All
      patients will receive durvalumab and radiation therapy during cycles 1-3. Radiation therapy
      is administered per standard radiation oncology regimens, on a daily basis and/or as
      scheduled during a Monday-Friday working week. Radiation therapy is given concurrently with
      durvalumab during Cycles 1-3. Durvalumab treatment (1500 mg Q3W) Cycles 1-3 are 3-weeks long
      cycles (total of 9 weeks). Radiation therapy will be delivered at a dose of 2 Gy over 30
      fractions totalling a final dose of 60 Gy. Radiation treatment will take 6 weeks (Mon-Fri) or
      30 days and will occur for 6 of 9 weeks that define Cycles 1-3. However, due to delays or
      missed appointments, completion of those 30 fractions may take longer than the allotted 6
      weeks and this is allowed. Radiation therapy must be scheduled and completed within Cycles
      1-3 and should not extend into Cycle 4. Please refer to Section 6.2 for additional details
      and allowances.

      During Cycle 4-6, only durvalumab 1500mg Q4W will be given.

      Duration of Follow Up All patients will be followed for up to 5 years, or until death,
      whichever occurs first after removal from study treatment for determination of study
      endpoints. Patients removed from study treatment for unacceptable adverse event (AE)s will be
      followed for resolution or stabilization of the adverse event(s). All patients (including
      those withdrawn for AEs) should be followed after removal from study treatment as stipulated
      in the protocol.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Disease-free Survival Status

Secondary Outcome

 Acute toxicities of adjuvant durvalumab with radiotherapy

Condition

Larynx

Intervention

Durvalumab

Study Arms / Comparison Groups

 Open-label, single-arm
Description:  Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

33

Start Date

October 7, 2019

Completion Date

February 15, 2026

Primary Completion Date

February 15, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Written informed consent obtained to participate in the study and HIPAA authorization
             for release of personal health information. Consent for the use of any residual
             material from biopsy (archival tissue) and serial blood draws will be required for
             enrollment.

          -  Age ≥ 18 years of age on day of signing informed consent

          -  ECOG Performance Status of 0 or 1 (See Appendix 12.4: ECOG Performance Status)

          -  Histologically confirmed squamous cell carcinoma of the head and neck, including the
             following subtypes: oral cavity, oropharynx, hypopharynx, larynx

          -  Must have undergone gross total resection of the primary tumor with curative intent
             within the past 8 weeks with surgical pathology demonstrating ≥ 1 of the following
             criteria for "intermediate" risk of recurrence:

               -  perineural invasion

               -  lymphovascular invasion

               -  single lymph node > 3 cm or at least 2 nodes without evidence of extracapsular
                  extension

               -  close margins defined as < 5 mm but not frankly positive (in the case of
                  ambiguous, controversial, or superseded margins, final clinical assessment
                  regarding margin status will prevail)

               -  pathologically confirmed T3 or T4 primary tumor

          -  No prior therapy to primary tumor prior to surgical resection (no induction therapy or
             recurrent disease).

          -  Demonstrated adequate organ function as defined in the protocol

          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             within 7 days prior to treatment. NOTE: Females are considered of child bearing
             potential unless they are surgically sterile (have undergone a hysterectomy, bilateral
             tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at
             least 12 consecutive months. Documentation of postmenopausal status must be provided.

          -  WOCBP must be willing to abstain from heterosexual activity or to use at least 1
             highly effective method of contraception from the time of informed consent until 90
             days after durvalumab monotherapy treatment is discontinued (whichever is longer). See
             section 5.6 of the protocol for additional details on contraception requirements for
             WOCBP and male participants in this trial.

          -  Male patients with female partners must have had a prior vasectomy or agree to use an
             adequate method of contraception (i.e., double barrier method: condom plus spermicidal
             agent) starting with the first dose of study therapy through 90 days after durvalumab
             monotherapy is discontinued.

          -  Subjects must be willing and able to comply with study procedures based on the
             judgment of the investigator or protocol designee.

        Exclusion Criteria:

        Subjects meeting any of the following exclusion criteria will not be able to participate in
        this study:

          -  Is currently participating in or has participated in a study of an investigational
             agent or an investigational device within 4 weeks of the first dose of treatment.

          -  Concurrent enrollment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study.

          -  Has evidence of metastatic disease at time of diagnosis

          -  Is receiving concurrent chemotherapy, investigational drug, biologic, or hormonal
             therapy for cancer treatment. Concurrent use of hormonal therapy for
             non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.

          -  Treatment with any investigational drug within 28 days or 5 half-lives of Day 1 of
             treatment on this study, whichever is shortest.

          -  Has not received any antibiotics <7 days prior to 1st dose of durvalumab. If the
             patient receives either IV antibiotics or >5 day treatment course (oral or IV), then
             the 1st durvalumab dose should not be given until 14 days of last antibiotic dose.
             During eligibility screening, subjects who receive any antibiotics within 30 days
             prior to the proposed initial infusion of durvalumab should be flagged and reviewed by
             the site's Principle Investigator to determine if the subject is a good candidate to
             receive durvalumab.

          -  Known allergy or hypersensitivity to durvalumab or any of the study drug excipients.

          -  Prior randomization or treatment in a previous durvalumab clinical study regardless of
             treatment arm assignment.

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication)

          -  Has received systemic steroid therapy or any other form of immunosuppressive therapy
             within 7 days prior to the first dose of trial treatment.

          -  Active infection requiring systemic therapy including tuberculosis (clinical
             evaluation that includes clinical history, physical examination and radiographic
             findings, and TB testing in line with local practice), hepatitis B (known positive HBV
             surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus
             (positive HIV 1/2 antibodies).

               -  Patients with a past or resolved HBV infection (defined as the presence of
                  hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.

               -  Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase
                  chain reaction is negative for HCV RNA.

          -  Has a known contraindication to radiation therapy, including inherited syndromes
             associated with hypersensitivity to ionizing radiation such as Ataxia-Telangiectasia
             and Nijmegen Breakage Syndrome

          -  Has a history of uncontrolled liver disease (including but not limited to cirrhosis).

          -  Subjects with baseline weight ≤ 40kg (88 lbs).

          -  Female patients who are pregnant or breastfeeding (NOTE: breast milk cannot be stored
             for future use while the mother is being treated on study) or male or female patients
             of reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab monotherapy.

          -  History of another primary malignancy except for.

               -  Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of IP and of low potential risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  History of leptomeningeal carcinomatosis.

          -  Has an active autoimmune disease (or inflammatory disorders) requiring systemic
             treatment within the past 3 months or a documented history of clinically severe
             autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive
             agents. Subjects with inflammatory disorders (including inflammatory bowel disease
             [e.g., colitis or Crohn's disease], diverticulitis [with the exception of
             diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener
             syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis,
             hypophysitis, uveitis, etc]).

        The following are exceptions to this criterion:

          -  Subjects with vitiligo or alopecia or resolved childhood asthma/atopy

          -  Subjects who require intermittent use of bronchodilators or local steroid injections
             would not be excluded from the study.

          -  Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone
             replacement or with Sjorgen's syndrome will not be excluded from the study

          -  Any chronic skin condition that does not require systemic therapy

          -  Subjects without active HNSCC disease in the last 5 years may be included but only
             after consultation with the study physician

          -  Subjects with celiac disease controlled by diet alone

               -  Has a history of non-infectious pneumonitis that required steroids or evidence of
                  interstitial lung disease or current active, non-infectious pneumonitis.

               -  Major surgical procedure (as defined by the Investigator) within 21 days prior to
                  the first dose of investigational product (IP). Note: Local surgery of isolated
                  lesions for palliative intent is acceptable.

               -  Uncontrolled intercurrent illness, including but not limited to, ongoing or
                  active infection, symptomatic congestive heart failure, uncontrolled
                  hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung
                  disease, serious chronic gastrointestinal conditions associated with diarrhea, or
                  psychiatric illness/social situations that would limit compliance with study
                  requirement, substantially increase risk of incurring AEs or compromise the
                  ability of the patient to give written informed consent.

               -  Receipt of live attenuated vaccine within 30 days prior to the first dose of
                  study drug. Note: Patients, if enrolled, should not receive live vaccine whilst
                  receiving study treatment and up to 30 days after the last dose of study
                  treatment.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jared Weiss, MD, 919-966-4432, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03529422

Organization ID

LCCC 1725


Responsible Party

Sponsor

Study Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

 AstraZeneca

Study Sponsor

Jared Weiss, MD, Principal Investigator, UNC Lineberger Comprehensive Cancer Center


Verification Date

April 2021